DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,…
Read More
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio,…
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio,…
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio,…
Vid extra bolagsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 14 december 2023 fattades följande beslut. För mer detaljerad information om…
Vid årsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 14 december 2023 fattades de beslut som beskrivs nedan. För mer detaljerad…
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio,…
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio,…
Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, shares an update today about…
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections,…